348 related articles for article (PubMed ID: 7577484)
1. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
2. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
5. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study.
Rotstein S; Glas U; Eriksson M; Pfeiffer P; Hansen J; Söderqvist J; Bandmann U; Strid S
Eur J Cancer; 1992; 28A(4-5):890-3. PubMed ID: 1388038
[TBL] [Abstract][Full Text] [Related]
6. Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia.
Atula ST; Tähtelä RK; Nevalainen JI; Pylkkänen LH
Acta Oncol; 2003; 42(7):735-40. PubMed ID: 14690159
[TBL] [Abstract][Full Text] [Related]
7. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
[TBL] [Abstract][Full Text] [Related]
8. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the role of bisphosphonates in metastatic disease.
Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
Jagdev SP; Purohit P; Heatley S; Herling C; Coleman RE
Ann Oncol; 2001 Oct; 12(10):1433-8. PubMed ID: 11762816
[TBL] [Abstract][Full Text] [Related]
11. Should bisphosphonates be standard therapy for bone pain?
Paterson AH
Support Care Cancer; 1997 May; 5(3):200-4. PubMed ID: 9176965
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
13. Treatment of malignant hypercalcaemia with clodronate.
Percival RC; Paterson AD; Yates AJ; Beard DJ; Douglas DL; Neal FE; Russell RG; Kanis JA
Br J Cancer; 1985 May; 51(5):665-9. PubMed ID: 3158326
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
15. [Osteolytic metastases of breast cancer and biphosphonates].
Lortholary A; Alleaume C; Pein F; Larra F
Rev Med Interne; 1992; 13(3):238-42. PubMed ID: 1410908
[TBL] [Abstract][Full Text] [Related]
16. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Gurney H; Kefford R; Stuart-Harris R
Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Fitton A; McTavish D
Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
[TBL] [Abstract][Full Text] [Related]
18. [Biphosphonate therapy in the management of skeletal metastases].
Grauer A; Ziegler R
Orthopade; 1998 Apr; 27(4):231-9. PubMed ID: 9616882
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.
Ralston SH; Gallacher SJ; Patel U; Dryburgh FJ; Fraser WD; Cowan RA; Boyle IT
Lancet; 1989 Nov; 2(8673):1180-2. PubMed ID: 2572902
[TBL] [Abstract][Full Text] [Related]
20. [Diphosphonates in the treatment of hypercalcemia].
Delmas PD; Meunier PJ
Rev Med Interne; 1984 Nov; 5(4):363-6. PubMed ID: 6240753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
